



*Certificate delivered by the European Commission,
as the institution managing Horizon 2020,
the EU Framework Programme for Research and Innovation 2014-2020*

The project proposal **784135, PSORIMARINE**

Clinical evaluation of first topical IL-1 beta inhibitor in mild to moderate psoriasis

Submitted under the Horizon 2020's **SME instrument phase 2**
call **H2020-SMEInst-2016-2017 (H2020-SMEINST-2-2016-2017)** of **1 June 2017**
in the area of **SMEInst-03-2016-2017**

Dedicated support to biotechnology SMEs closing the gap from lab to market

by

Regenics AS

Karvesvingen 2
0579 Oslo
Norway

following evaluation by an international panel of independent experts

**WAS SCORED AS A HIGH-QUALITY PROJECT PROPOSAL
IN A HIGHLY COMPETITIVE EVALUATION PROCESS***

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Cretu,
Commissioner for
Regional Policy

Carlos Moedas
Commissioner for Research
Science and Innovation

Brussels, 14/07/2017